BIOMAT Database Logo BIOMAT Database Logo

Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial. 1996

T van Gelder, and R Zietse, and J N Yzermans, and J Rischen-Vos, and L M Vaessen, and W Weimar
Department of Internal Medicine, University Hospital Rotterdam, The Netherlands.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

T van Gelder, and R Zietse, and J N Yzermans, and J Rischen-Vos, and L M Vaessen, and W Weimar
Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
January 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
T van Gelder, and R Zietse, and J N Yzermans, and J Rischen-Vos, and L M Vaessen, and W Weimar
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
November 2013, Lancet (London, England),
T van Gelder, and R Zietse, and J N Yzermans, and J Rischen-Vos, and L M Vaessen, and W Weimar
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
June 2004, Arthritis and rheumatism,
T van Gelder, and R Zietse, and J N Yzermans, and J Rischen-Vos, and L M Vaessen, and W Weimar
Pharmacodynamics of prophylactic antirejection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation.
September 1995, Immunopharmacology,
T van Gelder, and R Zietse, and J N Yzermans, and J Rischen-Vos, and L M Vaessen, and W Weimar
A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
August 1998, Clinical transplantation,
T van Gelder, and R Zietse, and J N Yzermans, and J Rischen-Vos, and L M Vaessen, and W Weimar
Prophylactic treatment of human kidney allograft recipients with a monoclonal antibody (33B3.1) directed against interleukin 2 receptor.
April 1988, Transplantation proceedings,
T van Gelder, and R Zietse, and J N Yzermans, and J Rischen-Vos, and L M Vaessen, and W Weimar
Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.
August 1998, Transplantation proceedings,
T van Gelder, and R Zietse, and J N Yzermans, and J Rischen-Vos, and L M Vaessen, and W Weimar
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
January 2010, Gut,
T van Gelder, and R Zietse, and J N Yzermans, and J Rischen-Vos, and L M Vaessen, and W Weimar
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
September 2015, Lancet (London, England),
T van Gelder, and R Zietse, and J N Yzermans, and J Rischen-Vos, and L M Vaessen, and W Weimar
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
December 2002, Arthritis and rheumatism,
Copied contents to your clipboard!